Ensysce Biosciences ENSC Estimates

NASDAQ ENSC
$0.47 +0.00 (+0.30%)
As of: Sep 9, 2026 · 3:59 PM EDT
Analyst Estimates

Ensysce Biosciences, Inc. Revenue Estimates

Periods 18
Next Period Q2 25
Consensus 622,514.75

Analysts expect Ensysce Biosciences, Inc. to report revenue of 622,514.75 for Q2 25, against a range of 585,929.56 to 659,099.94. The most recent reported quarter, Q2 26, came in at 1.20 M, a 5.3% beat against the 1.14 M consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 3.41 M1.30 M1.31 M-493,100.001.90 M1.00 M1.20 M-------
High Estimate 3.95 M265,810.790.00659,099.94723,892.83548,257.991.91 M1.19 M1.21 M1.20 M551,765.33633,030.40682,526.25843,806.54453,724.23
Low Estimate 3.32 M236,983.110.00585,929.56634,548.17490,827.731.66 M1.09 M1.10 M1.07 M471,600.01592,789.20599,179.49772,832.84412,060.09
Consensus Estimate 3.63 M251,396.950.00622,514.75679,220.50519,542.861.78 M1.14 M1.15 M1.13 M511,682.67612,909.80640,852.87808,319.69432,892.16
Analyst Estimates

Ensysce Biosciences, Inc. Earnings Per Share (EPS) Estimates

Periods 18
Next Period Q3 26
Consensus -0.20

Analysts expect Ensysce Biosciences, Inc. to report earnings per share of -0.20 for Q3 26, against a range of -0.21 to -0.19. The most recent reported quarter, Q2 26, came in at -0.20, a 5.3% miss against the -0.19 consensus.

Metric Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27Q1 28Q2 28Q3 28Q4 28
Reported (Actual) 1.05-2.90-1.39-0.79-1.29-0.75-0.52-0.20--------
High Estimate 1.10-2.43-2.71-0.89-0.80-1.12-0.62-0.18-0.19-0.160.150.33-0.19-0.300.941.06
Low Estimate 0.92-2.81-3.07-1.07-0.92-1.30-0.74-0.20-0.21-0.180.130.29-0.21-0.340.840.90
Consensus Estimate 1.01-2.62-2.89-0.98-0.86-1.21-0.68-0.19-0.20-0.170.140.31-0.20-0.320.890.98